title: Regional citrate anticoagulation in continuous venovenous haemofiltration using commercial preparations.
abstract: OBJECTIVE
  The aim of the present study was to test the feasibility of using commercial preparations of replacement and citrate anticoagulation solution in continuous venovenous haemofiltration (CVVH) in a safe, efficient and simple manner.
  
  
  METHODS
  Retrospective review of the database of a large continuous renal replacement therapy programme that uses a standardized prescription of high ultrafiltrate CVVH with commercial solutions for replacement fluid and regional citrate anticoagulation was performed.
  
  
  RESULTS
  Records of 28 patients who underwent 91 CVVH sessions were analysed. Median circuit survival time was 37 (59.5-15.5) h and the 48 h survival probability was 40%. Bleeding or metabolic complications were not noted, and the procedure was simple to administer.
  
  
  CONCLUSIONS
  Continuous venovenous haemofiltration using commercial preparations of replacement fluid and citrate anticoagulation can be safe, efficient and simple.
authors.affiliation: Division of Nephrology, Hypertension and Transplantation, University of Florida, Gainesville, Florida 32610-0224, USA.
authors.forename: Sandeep
authors.initials: S
authors.lastname: Munjal
authors.forename: A Ahsan
authors.initials: AA
authors.lastname: Ejaz
mesh_terms: D058186:Acute Kidney Injury / Q000401:mortality / Q000628:therapy*; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D019343:Citric Acid / Q000627:therapeutic use*; D005260:Female; D005947:Glucose / Q000627:therapeutic use; D006440:Hemofiltration / Q000379:methods*; D006801:Humans; D007552:Isotonic Solutions; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000925:Anticoagulants; D007552:Isotonic Solutions; D019343:Citric Acid; D005947:Glucose